Effects of nanocurcumin supplementation on T-helper 17 cells inflammatory response in patients with Behcet's disease: a randomized controlled trial.
Rojin FarzanehAlireza KhabbaziMohammad Sadegh Soltani-ZangbarSamaneh AbbasianAida Malek MahdaviRoza MotavalliMehdi YousefiPublished in: Immunopharmacology and immunotoxicology (2022)
Nanocurcumin supplementation had favorable effects in improving inflammatory factors and disease activity in BD patients. Additional studies are warranted to suggest nanocurcumin as a safe complementary therapy in BD.HighlightsNanocurcumin supplementation decreased Th17 cells frequency significantly compared with baseline and placebo group.Nanocurcumin supplementation decreased mRNA expression of RORγt, IL-17, IL-23, miRNA-155, miRNA-181, and miRNA-326 significantly compared to baseline and placebo group.Nanocurcumin supplementation decreased cell supernatant IL-17 and IL-23 significantly compared to baseline and placebo group.Nanocurcumin supplementation decreased disease activity significantly compared to placebo group.
Keyphrases
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- rheumatoid arthritis patients
- inflammatory response
- induced apoptosis
- ankylosing spondylitis
- juvenile idiopathic arthritis
- cell cycle arrest
- end stage renal disease
- ejection fraction
- phase iii
- randomized controlled trial
- stem cells
- immune response
- single cell
- endoplasmic reticulum stress
- signaling pathway
- cell proliferation
- prognostic factors
- cell therapy
- cell death
- dendritic cells